Medicare AdvantageDocumentationMedium impact
MA08.129b, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.129b establishes medical necessity criteria and coding requirements for Phesgo® (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf), a combination therapeutic agent used in oncology. The policy became effective November 17, 2025, and modifies how claims for this medication must be coded and justified for Medicare Advantage plans.
Action Required
By November 17, 2025: Billing team must review the complete MA08.129b policy text to identify specific medical necessity criteria, required documentation, and applicable HCPCS/CPT codes for Phesgo® administration. Update billing system edits and encounter templates to enforce the new medical necessity requirements. Providers must document how patient cases meet the stated criteria before submitting claims. Coordinate with oncology providers to ensure compliance with updated coding requirements. Claims not meeting documented medical necessity criteria will be denied. Access the full policy at: https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma08-129b-pertuzumab-trastuzumab-and-hyal